Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial

INTRODUCTION: Finding the optimal management strategy for patients with advanced, metastatic neuroendocrine tumours (NETs) of the gastrointestinal tract and pancreas is a work in progress. Sunitinib and everolimus are currently approved for the treatment of progressive, unresectable, locally advance...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMJ Open
Autors principals: Neychev, Vladimir, Steinberg, Seth M, Cottle-Delisle, Candice, Merkel, Roxanne, Nilubol, Naris, Yao, Jianhua, Meltzer, Paul, Pacak, Karel, Marx, Stephen, Kebebew, Electron
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2015
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4442235/
https://ncbi.nlm.nih.gov/pubmed/25991462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2015-008248
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars